Alaunos Therapeutics, Inc. (TCRT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2.5M 5M 7.5M Q4 '11: 667K Q1 '12: 800K Q2 '12: 800K Q3 '12: 800K Q4 '12: 800K Q1 '13: 800K Q2 '13: 800K Q3 '13: 800K Q4 '13: 800K Q4 '17: 6.4M Q1 '18: 4.9M Q2 '18: 3.3M Q3 '18: 1.7M Q4 '18: 146K Q4 '20: 0 Q2 '22: 398K Q3 '22: 2.9M Q4 '22: 2.9M Q1 '23: 2.9M Q2 '23: 2.9M Q3 '23: 15K Q4 '23: 5K Q1 '24: 6K Q2 '24: 6K Q3 '24: 6K Q4 '24: 9K Q1 '25: 10K Q2 '25: 6K Q3 '25: 6K Q4 '25: 5K Q1 '26: 3K Q2 '26: 3K Q3 '12 Q3 '13 Q2 '18 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q2 '10: -16.3M Q3 '10: -22.2M Q4 '10: -24.5M Q1 '11: -47.9M Q2 '11: -55.6M Q3 '11: -61.3M Q4 '11: -71.4M Q1 '12: -62.1M Q2 '12: -72.2M Q3 '12: -79.7M Q4 '12: -102.2M Q1 '13: -107.1M Q2 '13: -102.4M Q1 '14: -43.9M Q2 '14: -36.8M Q3 '14: -39.6M Q4 '14: -43.5M Q1 '15: -111.9M Q2 '15: -115M Q3 '15: -121.2M Q2 '16: -170.9M Q3 '16: -163.7M Q2 '17: -49M Q3 '17: -51.2M Q4 '17: -53.5M Q1 '18: -55.7M Q2 '18: -55.1M Q3 '18: -54.6M Q4 '18: -53.9M Q1 '19: -51.3M Q2 '19: -53.7M Q3 '19: -54.6M Q4 '19: -57.9M Q1 '20: -62.9M Q2 '20: -66.8M Q3 '20: -73.6M Q4 '20: -80.4M Q1 '21: -83.3M Q2 '21: -87.3M Q3 '21: -89.3M Q4 '21: -77.5M Q1 '22: -65.1M Q2 '22: -51.7M Q3 '22: -37.6M Q4 '22: -35.1M Q1 '23: -35.7M Q2 '23: -34.4M Q3 '23: -34.8M Q4 '23: -34.3M Q1 '24: -26.3M Q2 '24: -19.5M Q3 '24: -12M Q4 '24: -4.8M Q1 '25: -4.2M Q2 '25: -4M Q3 '25: -4.1M Q4 '25: -4.2M Q1 '26: -4.1M Q2 '26: -4.1M Q4 '10 Q4 '12 Q2 '15 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '10: -32.7M Q1 '11: -54M Q2 '11: -73.8M Q3 '11: -62.4M Q4 '11: -63.8M Q1 '12: -49.2M Q2 '12: -62.1M Q3 '12: -79.2M Q4 '12: -96.1M Q1 '13: -84.5M Q2 '13: -79.5M Q1 '14: -54M Q2 '14: -40.9M Q3 '14: -30.3M Q4 '14: -31.8M Q1 '15: -100.3M Q2 '15: -108.9M Q3 '15: -121M Q2 '16: -170.9M Q3 '16: -167.1M Q2 '17: -54M Q3 '17: -55.8M Q4 '17: -59.3M Q1 '18: -59.9M Q2 '18: -59M Q3 '18: -58.9M Q4 '18: 153.9M Q1 '19: 156.5M Q2 '19: 153.9M Q3 '19: 92.5M Q4 '19: -117.8M Q1 '20: -122.7M Q2 '20: -126.6M Q3 '20: -73M Q4 '20: -80M Q1 '21: -83.2M Q2 '21: -87.3M Q3 '21: -89.7M Q4 '21: -78.8M Q1 '22: -67M Q2 '22: -54.2M Q3 '22: -40.4M Q4 '22: -37.7M Q1 '23: -38M Q2 '23: -36.8M Q3 '23: -36.5M Q4 '23: -4.7M Q1 '24: 3.7M Q2 '24: 11.3M Q3 '24: 18.7M Q4 '24: -4.7M Q1 '25: -4.1M Q2 '25: -4M Q3 '25: -4M Q4 '25: -4.2M Q1 '26: -4.1M Q2 '26: -4M Q4 '10 Q4 '12 Q2 '15 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q2 '11: -25.6M Q3 '11: -30.9M Q4 '11: -38.8M Q1 '12: -56.5M Q2 '12: -67.5M Q3 '12: -71.1M Q4 '12: -78.8M Q1 '13: -71.2M Q2 '13: -71.2M Q3 '13: -72M Q4 '13: -59.5M Q1 '14: -49.9M Q2 '14: -40.8M Q3 '14: -35.8M Q4 '14: -36.6M Q1 '15: -37.7M Q2 '15: -41.8M Q3 '15: 13.9M Q4 '15: -10K Q1 '16: -6.4M Q2 '16: -9.8M Q3 '16: -69.1M Q4 '16: -58.3M Q1 '17: -56.5M Q2 '17: -57M Q3 '17: -55.6M Q4 '17: -54.7M Q1 '18: -59.3M Q2 '18: -54M Q3 '18: -49.8M Q4 '18: -49.5M Q1 '19: -40.7M Q2 '19: -38.6M Q3 '19: -41.1M Q4 '19: -40.9M Q1 '20: -40.5M Q2 '20: -46.4M Q3 '20: -51.6M Q4 '20: -57M Q1 '21: -62.4M Q2 '21: -69.9M Q3 '21: -63.4M Q4 '21: -61.5M Q1 '22: -53.9M Q2 '22: -40.7M Q3 '22: -37.2M Q4 '22: -29.2M Q1 '23: -30.8M Q2 '23: -29.7M Q3 '23: -29.9M Q4 '23: -30.1M Q1 '24: -22.7M Q2 '24: -17.4M Q3 '24: -11.8M Q4 '24: -5M Q1 '25: -3.8M Q2 '25: -2.8M Q3 '25: -2.9M Q4 '25: -2.9M Q1 '26: -3.1M Q2 '26: -2.7M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q2 '11: -26.1M Q3 '11: -31.7M Q4 '11: -40M Q1 '12: -57.6M Q2 '12: -69.3M Q3 '12: -72.9M Q4 '12: -80.4M Q1 '13: -72.7M Q2 '13: -71.7M Q3 '13: -72.2M Q4 '13: -59.6M Q1 '14: -49.9M Q2 '14: -41M Q3 '14: -36M Q4 '14: -36.8M Q1 '15: -37.9M Q2 '15: -41.9M Q3 '15: 13.9M Q4 '15: -422K Q1 '16: -6.9M Q2 '16: -10.4M Q3 '16: -69.9M Q4 '16: -58.9M Q1 '17: -57.3M Q2 '17: -57.7M Q3 '17: -56.1M Q4 '17: -55.4M Q1 '18: -59.9M Q2 '18: -54.7M Q3 '18: -50.6M Q4 '19: -41.1M Q1 '20: -41.3M Q2 '20: -50.7M Q3 '20: -57.7M Q4 '20: -66.8M Q1 '21: -72.4M Q2 '21: -78.2M Q3 '21: -70.1M Q4 '21: -64.8M Q1 '22: -56.6M Q2 '22: -41.5M Q3 '22: -37.7M Q4 '22: -29.4M Q1 '23: -31.1M Q2 '23: -30M Q3 '23: -30.2M Q4 '23: -30.3M Q1 '24: -22.8M Q2 '24: -17.4M Q3 '24: -11.8M Q4 '24: -5M Q3 '11 Q2 '13 Q1 '15 Q4 '16 Q3 '18 Q2 '21 Q1 '23 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '09: 21.8M Q2 '10: 48.8M Q3 '10: 47.4M Q2 '11: 67.2M Q3 '11: 68.1M Q2 '12: 78.5M Q3 '12: 78.7M Q2 '21: 214.4M Q3 '21: 214.5M Q1 '22: 214.9M Q2 '22: 215M Q3 '22: 215.1M Q1 '23: 16M Q2 '23: 1.6M Q3 '23: 1.6M Q1 '24: 1.6M Q2 '24: 1.6M Q3 '24: 1.6M Q1 '25: 1.6M Q2 '25: 1.7M Q3 '25: 2.2M Q1 '26: 1.9M Q2 '26: 2.4M Q2 '10 Q3 '11 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '11: -1.01 Q1 '12: -0.68 Q2 '12: -0.82 Q3 '12: -1.04 Q4 '12: -1.22 Q1 '13: -1.05 Q2 '13: -0.97 Q1 '14: -0.61 Q2 '14: -0.45 Q3 '14: -0.31 Q4 '14: -0.31 Q1 '15: -0.90 Q2 '15: -0.95 Q3 '15: -1.03 Q2 '16: -1.31 Q3 '16: -1.28 Q2 '17: -0.50 Q3 '17: -0.52 Q4 '17: -0.53 Q1 '18: -0.53 Q2 '18: -0.52 Q3 '18: -0.52 Q4 '18: 0.89 Q1 '19: 0.96 Q2 '19: 0.99 Q3 '19: 0.69 Q4 '19: -0.69 Q1 '20: -0.70 Q2 '20: -0.70 Q3 '20: -0.37 Q4 '20: -0.39 Q1 '21: -0.40 Q2 '21: -0.42 Q3 '21: -0.43 Q4 '21: -0.38 Q1 '22: -0.33 Q2 '22: -0.27 Q3 '22: -0.20 Q4 '22: -2.62 Q1 '23: -3.20 Q2 '23: -8.64 Q3 '23: -13.90 Q4 '23: -16.32 Q1 '24: -16.74 Q2 '24: -11.96 Q3 '24: -7.36 Q4 '24: -2.92 Q1 '25: -2.54 Q2 '25: -2.46 Q3 '25: -2.31 Q4 '25: -2.21 Q1 '26: -2.13 Q2 '26: -1.91 Q3 '12 Q4 '14 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.